

Request Information

Permalink

# Anti-CD94 Antibodies for Enhanced Immune Response to Cancer Cells

Tech ID: 33619 / UC Case 2020-221-0

## TECHNOLOGY DESCRIPTION

Current cancer therapies often have limitations such as off-target effects, development of resistance, and limited efficacy against certain cancer types. There is a pressing need for therapies that can specifically target cancer cells and enhance the body’s natural immune response against these malignant cells. The inventors have developed a novel therapeutic approach that uses anti-CD94 antibodies to deplete NK cells in a cancer patient.

## APPLICATION

This method enhances the targeting and killing of cancer cells by activated T cells, such as CD8+ effector T cells. The anti-CD94 antibodies can be administered in conjunction with other therapies like checkpoint inhibitors and antigen administration for cancer antigens. The antibodies can also be used to reduce an NK cell-mediated immune response to non-self cells or tissues transplanted in an individual, thereby enhancing the effectiveness of therapies such as CAR T-cell therapy.

## DATA AVAILABILITY

The inventors have shown specific binding regions and potential for high affinity binding to CD94.

## PATENT STATUS

Country	Type	Number	Dated	Case
China	Published Application	116829185	04/05/2024	2020-221

Additional Patents Pending

### CONTACT

Gemma E. Rooney  
[Gemma.Rooney@ucsf.edu](mailto:Gemma.Rooney@ucsf.edu)  
tel: 415-625-9093.



### OTHER INFORMATION

#### KEYWORDS

CD94, Antibody, Antibodies,  
NK Cells, CD8+ T cells,  
CAR-T cell therapy

#### CATEGORIZED AS

- Medical
- Disease: Cancer
- Therapeutics

#### RELATED CASES

2020-221-0

